Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Trial Profile

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2016

At a glance

  • Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 17 Apr 2016 Results assessing pharmacokinetics of Abt-493 and Abt-530 combination therapy presented at The International Liver Congress 2016.
    • 20 Oct 2015 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 16 Oct 2015 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top